50790-30-2

Usage

Uses

Used in Organic Synthesis:
N-(3-Cyanophenyl)methanesulfonamide is used as a reagent in organic synthesis for the formation and modification of carbon-carbon and carbon-nitrogen bonds. Its ability to facilitate these bond formations makes it a valuable component in creating complex organic molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, N-(3-Cyanophenyl)methanesulfonamide is utilized as a building block for the synthesis of various pharmaceutical compounds. Its structural properties allow it to be a key constituent in the development of new drugs.
Used in Medicinal Chemistry Research:
N-(3-Cyanophenyl)methanesulfonamide is studied for its potential biological activities in medicinal chemistry research. Its antimicrobial and antitumor properties make it a subject of interest for the development of treatments for infectious diseases and cancer, respectively.
Used in Antimicrobial Applications:
N-(3-Cyanophenyl)methanesulfonamide is used as an antimicrobial agent for its potential to combat various microorganisms. Its activity in this area could contribute to the development of new antibiotics or antifungal agents.
Used in Antitumor Applications:
In the realm of antitumor applications, N-(3-Cyanophenyl)methanesulfonamide is explored for its capacity to inhibit tumor growth. Its potential to be a component in anti-cancer drugs is under investigation, which could lead to advancements in cancer treatment.

InChI:InChI=1/C8H8N2O2S/c1-13(11,12)10-8-4-2-3-7(5-8)6-9/h2-5,10H,1H3

Upstream product

• 124-63-0 methanesulfonyl chloride 
• 2237-30-1 m-cyanoaniline 

Downstream Products

• 1089581-43-0 C₁₅H₁₄N₂O₂S 
• 2307461-45-4 C₂₅H₂₈F₃N₅O₆S 
• 869371-36-8 N-(3-(aminomethyl)phenyl)-N-methylmethanesulfonamide 
• 597561-37-0 N-(3-cyanophenyl)-N-methylmethanesulfonamide 

Relevant academic research and scientific papers

BIFUNCTIONAL SUBSTITUED PYRIMIDINES AS MODULATORS OF FAK PROTEOLYSE

The present disclosure relates to bifunctional compounds, which find utility as modulators of focal adhesion kinase (FAK) or protein tyrosine kinase 2 (PTK2). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

Addressing Kinase-Independent Functions of Fak via PROTAC-Mediated Degradation

Enzymatic inhibition has proven to be a successful modality for the development of many small-molecule drugs. In recent years, small-molecule-induced protein degradation has emerged as an orthogonal therapeutic strategy that has the potential to expand the druggable target space. Focal adhesion kinase (Fak) is a key player in tumor invasion and metastasis, acting simultaneously as a kinase and a scaffold for several signaling proteins. While previous efforts to modulate Fak activity were limited to kinase inhibitors with low success in clinical studies, protein degradation offers a possibility to simultaneously block Fak's kinase signaling and scaffolding capabilities. Here, we report the development of a selective and potent Fak degrader, PROTAC-3, which outperforms a clinical candidate, defactinib, with respect to Fak activation as well as Fak-mediated cell migration and invasion. These results underline the potential that PROTACs offer in expanding the druggable space and controlling protein functions that are not easily addressed by traditional small-molecule therapeutics.

HETEROARYL-PYRAZOLE DERIVATIVE

A compound represented by formula [I] and a pharmaceutically accepted salt of said compound are a novel compound and a pharmaceutically accepted salt thereof which exert antagonistic activity against group II metabotropic glutamate (mGlu) receptors, and are effective as a novel preventive or therapeutic agent for disorders such as mood disorders (depressive disorder, bipolar disorder, etc.), anxiety disorders (generalized anxiety disorder, panic disorder, obsessive-compulsive disorder, social anxiety disorder, posttraumatic stress disorder, a specific phobic disorder, acute stress disorder, etc.), schizophrenia, Alzheimer's disease, cognitive impairment, dementia, drug dependence, convulsions, shivering, pain, sleep disorders, and the like.

PYRROLOPYRIMIDINES AS FAK AND ALK INHIBITERS FOR TREATMENT OF CANCERS AND OTHER DISEASES

Disclosed are compounds which inhibit the activity of focal adhesion kinase (FAK) and anaplastic lymphoma kinase (ALK), compositions containing the compounds, and methods of treating diseases during which FAK and ALK are expressed. The diseases are, for example, cancers.

SULFONYL AMIDE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH

The present invention relates to a compound of the formula I wherein R1 to R6, A, B, n and m are as defined herein. Such novel sulfonyl amide derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

Substituent effects in infrared spectroscopy-VII. Meta and para substituted methanesulphonanilides

Substituent effects on the NH frequencies of the conformers of methanesulphonanilides, their cyclic dimers and their hydrogen bonded complexes with acetonitrile have been analysed by means of the Hammet equation.An electron-withdrawing substituent may either increase or decrease ν(NH) in the XC6H4NHY series according to the electronic nature of the Y group.This can be explained by the non-monotonic dependence of the NH stretching frequency on the ionic character of the NH bond.